达必达与达贝泊汀治疗慢性肾功能衰竭贫血的疗效和安全性：随机对照试验的系统评价和荟萃分析

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of pharmacological sciences Pub Date : 2025-03-15 DOI:10.1016/j.jphs.2025.03.006

Shuyue Pang , Zhongtian Wang , Yanyan Fu , Xu Huang

{"title":"达必达与达贝泊汀治疗慢性肾功能衰竭贫血的疗效和安全性：随机对照试验的系统评价和荟萃分析","authors":"Shuyue Pang , Zhongtian Wang , Yanyan Fu , Xu Huang","doi":"10.1016/j.jphs.2025.03.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To compare the efficacy and safety of daprodustat (DPD) versus darbepoetin alfa (DBPA) in patients with anemia in chronic renal failure.</div></div><div><h3>Materials and methods</h3><div>Randomized controlled trials (RCTs) of DPD and DBPA in anemia were retrieved from PubMed, Embase, Cochrane library, and Web of Science from inception to August 1, 2023. The collected data were analyzed using Stata 15.0.</div></div><div><h3>Results</h3><div>Four RCTs involving 7419 patients (3717 in the DPD group and 3702 in the DBPA group) were included in the study. Meta-analysis revealed that there were no significant differences in the change in hemoglobin level [Standardized Mean Difference (SMD) = 3.23, 95 % CI (−0.25, 6.70)], transferrin saturation [SMD = −0.07, 95 % CI (−0.31, 0.17)], total iron [SMD = 0.24, 95 % CI (−0.05, 0.53))], and incidence of adverse events [ RR = 1.02, 95 % CI (0.98, 1.06)] between the two groups. However, DPD was superior in lowering ferritin level [SMD = −0.05, 95 % CI (−0.10, −0.01)] and improving total iron-binding capacity [SMD = 0.57, 95 % CI (0.46, 0.68)] than DBPA.</div></div><div><h3>Conclusions</h3><div>DPD is not inferior to DBPA in the treatment of anemia in chronic renal failure.</div></div>","PeriodicalId":16786,"journal":{"name":"Journal of pharmacological sciences","volume":"158 1","pages":"Pages 68-75"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials\",\"authors\":\"Shuyue Pang , Zhongtian Wang , Yanyan Fu , Xu Huang\",\"doi\":\"10.1016/j.jphs.2025.03.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>To compare the efficacy and safety of daprodustat (DPD) versus darbepoetin alfa (DBPA) in patients with anemia in chronic renal failure.</div></div><div><h3>Materials and methods</h3><div>Randomized controlled trials (RCTs) of DPD and DBPA in anemia were retrieved from PubMed, Embase, Cochrane library, and Web of Science from inception to August 1, 2023. The collected data were analyzed using Stata 15.0.</div></div><div><h3>Results</h3><div>Four RCTs involving 7419 patients (3717 in the DPD group and 3702 in the DBPA group) were included in the study. Meta-analysis revealed that there were no significant differences in the change in hemoglobin level [Standardized Mean Difference (SMD) = 3.23, 95 % CI (−0.25, 6.70)], transferrin saturation [SMD = −0.07, 95 % CI (−0.31, 0.17)], total iron [SMD = 0.24, 95 % CI (−0.05, 0.53))], and incidence of adverse events [ RR = 1.02, 95 % CI (0.98, 1.06)] between the two groups. However, DPD was superior in lowering ferritin level [SMD = −0.05, 95 % CI (−0.10, −0.01)] and improving total iron-binding capacity [SMD = 0.57, 95 % CI (0.46, 0.68)] than DBPA.</div></div><div><h3>Conclusions</h3><div>DPD is not inferior to DBPA in the treatment of anemia in chronic renal failure.</div></div>\",\"PeriodicalId\":16786,\"journal\":{\"name\":\"Journal of pharmacological sciences\",\"volume\":\"158 1\",\"pages\":\"Pages 68-75\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmacological sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1347861325000271\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1347861325000271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的比较达生产司他（DPD）与达贝泊汀（DBPA）治疗慢性肾功能衰竭贫血患者的疗效和安全性。材料与方法从PubMed、Embase、Cochrane图书馆和Web of Science检索至2023年8月1日，DPD和DBPA在贫血中的随机对照试验（RCTs）。收集的数据使用Stata 15.0进行分析。结果共纳入4项随机对照试验，共7419例患者（DPD组3717例，DBPA组3702例）。meta分析显示，两组患者血红蛋白水平[标准化平均差(SMD) = 3.23, 95% CI(- 0.25, 6.70)]、转铁蛋白饱和度[SMD = - 0.07, 95% CI(- 0.31, 0.17)]、总铁[SMD = 0.24, 95% CI(- 0.05, 0.53))]、不良事件发生率[RR = 1.02, 95% CI(0.98, 1.06)]的变化无显著差异。但DPD在降低铁蛋白水平[SMD = - 0.05, 95% CI(- 0.10, - 0.01)]和提高总铁结合能力[SMD = 0.57, 95% CI(0.46, 0.68)]方面优于DBPA。结论sdpd治疗慢性肾功能衰竭贫血的疗效不逊于DBPA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials

Objectives

To compare the efficacy and safety of daprodustat (DPD) versus darbepoetin alfa (DBPA) in patients with anemia in chronic renal failure.

Materials and methods

Randomized controlled trials (RCTs) of DPD and DBPA in anemia were retrieved from PubMed, Embase, Cochrane library, and Web of Science from inception to August 1, 2023. The collected data were analyzed using Stata 15.0.

Results

Four RCTs involving 7419 patients (3717 in the DPD group and 3702 in the DBPA group) were included in the study. Meta-analysis revealed that there were no significant differences in the change in hemoglobin level [Standardized Mean Difference (SMD) = 3.23, 95 % CI (−0.25, 6.70)], transferrin saturation [SMD = −0.07, 95 % CI (−0.31, 0.17)], total iron [SMD = 0.24, 95 % CI (−0.05, 0.53))], and incidence of adverse events [ RR = 1.02, 95 % CI (0.98, 1.06)] between the two groups. However, DPD was superior in lowering ferritin level [SMD = −0.05, 95 % CI (−0.10, −0.01)] and improving total iron-binding capacity [SMD = 0.57, 95 % CI (0.46, 0.68)] than DBPA.

Conclusions

DPD is not inferior to DBPA in the treatment of anemia in chronic renal failure.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of pharmacological sciences 医学-药学

CiteScore

6.20

自引率

2.90%

发文量

104

审稿时长

31 days

期刊介绍： Journal of Pharmacological Sciences (JPS) is an international open access journal intended for the advancement of pharmacological sciences in the world. The Journal welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology for publication as Reviews, Full Papers or Short Communications. Short Communications are short research article intended to provide novel and exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanism and dose-response determinations are not acceptable and will be rejected without peer review. The ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.